Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Gynecologic 1Breast 1

Conditions

Pancreatic Neoplasms 22Stomach Neoplasms 19Ovarian Neoplasms 18Colorectal Neoplasms 18Melanoma 15Carcinoma, Hepatocellular 15Carcinoma, Non-Small-Cell Lung 12Breast Neoplasms 11Neoplasm Metastasis 10Uterine Cervical Neoplasms 9Esophageal Neoplasms 9Liver Neoplasms 7Head and Neck Neoplasms 7Anus Neoplasms 7Colonic Neoplasms 6Carcinoma, Renal Cell 6Vaginal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Penile Neoplasms 5Neoplasms 5Mesothelioma 5Lung Neoplasms 5Cholangiocarcinoma 5Triple Negative Breast Neoplasms 4Oropharyngeal Neoplasms 4Neuroblastoma 4Gastrointestinal Neoplasms 4Carcinoma, Merkel Cell 4Vulvar Neoplasms 3Urinary Bladder Neoplasms 3

Interventions

pembrolizumab 20Gemcitabine 10Nivolumab 8Irinotecan 8atezolizumab 7durvalumab 6Docetaxel 6sargramostim 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5aldesleukin 4Psychiatric Rehabilitation 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cisplatin 4tislelizumab 3spartalizumab 3avelumab 3Topotecan 3Therapeutics 3Polymerase Chain Reaction 3Carboplatin 3Bevacizumab 3tremelimumab 2talazoparib 2surufatinib 2regorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × fludarabine × Gastrointestinal × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04596033 2022-07-15

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Genocea Biosciences, Inc.

Phase 1 Terminated
49 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡